Probiotics for Gallstones in Post-bariatric Surgery Patients
NCT ID: NCT06287931
Last Updated: 2024-03-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
400 participants
INTERVENTIONAL
2024-01-01
2025-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Probiotics for Gallstones in Post-bariatric Surgery Patients：A Prospective Randomized Trial
NCT03247101
Preventive Therapy With Ursodiol to Reduce the Incidence of Gallstones Formation in Patients After Bariatric Surgery
NCT02319629
The Effects of Probiotic Supplementation on the Results of Gastric Bypass Surgery
NCT02708589
Prediction Model for Early Biliary Stasis After Bariatric Surgery
NCT06385860
Impact of a Pro-diversity Gut Microbiota Diet After a Bariatric Surgery on Gut Microbiota, Eating Behaviour and Sensory Function
NCT07268508
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ursodoxycholic acid group
Ursodoxycholic acid, 250mg po tid x 6 months
Ursodoxycholic acid group
Ursodoxycholic acid, 250mg po tid x 6 months
Bifidobacterium group
Bifidobacteria, 210 mg po tid x 6 months
Bifidobacterium group
Bifidobacteria, 210 mg po tid x 6 months
Bifidobacterium and ursodeoxycholic acid group
Ursodoxycholic acid, 250mg po tid x 6 months Bifidobacteria, 210 mg po tid x 6 months
Ursodoxycholic acid group
Ursodoxycholic acid, 250mg po tid x 6 months
Bifidobacterium group
Bifidobacteria, 210 mg po tid x 6 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ursodoxycholic acid group
Ursodoxycholic acid, 250mg po tid x 6 months
Bifidobacterium group
Bifidobacteria, 210 mg po tid x 6 months
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patiets at ages between 20 to 60 y/o
* Patients willing to follow up regulary after bariatric surgery
Exclusion Criteria
* Patients refusing taking probiotics or refusing regular follow up after bariatric surgery
20 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shandong Linglong Yingcheng Hospital
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xuan Qiu
MD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shandong Linglong Yingcheng Hospital
Yantai, Shandong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
sdllycyy001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.